Clinuvel Pharmaceuticals Ltd Sustainability Reports
Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing and delivering treatments for patients with severe genetic and skin disorders. Its principal product, SCENESSE, is a first-in-class drug developed for the treatment of erythropoietic protoporphyria.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 5299004VJH3VCYLK6519
FIGI: BBG001SFPXM9
18 reports from 2006 to 2026
